Phase 1/2A dose range finding study of IRL201805 in patients with active rheumatoid arthritis who had failed one or more standard therapies
Latest Information Update: 21 May 2022
At a glance
- Drugs IRL 201805 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Immune Regulation; Revolo Biotherapeutics
- 16 May 2022 According to a Revolo Biotherapeutics media release, this trial will be reviewed at the at two upcoming medical meetings: the American Thoracic Society (ATS) International Conference and the Treg Summit.
- 09 Sep 2020 New trial record
- 08 Sep 2020 Results published in the Media Release